Avicenna

A Breakthrough in Pharmacognosy

The 'Avicenna' nettle variety is the result of focused breeding efforts by authors V. I. Chernyavskikh, E. V. Dumacheva, A. M. Popov, and A. Yu. Chasovitin, aimed at establishing a reliable raw material base for the pharmaceutical industry. Unlike wild populations, this variety was developed to standardize phytochemical composition, which is critical for achieving consistent therapeutic effects during the processing of plant materials.

Technical Specifications and Yield Performance

• Metabolite Standardization: The variety's genetic architecture is optimized for high accumulation of biologically active substances (vitamins K, C, B, organic acids, and flavonoids), ensuring chemical profile stability across various growing conditions.
• Morphological Resilience: The plant exhibits high shoot-forming capacity. Breeders achieved an optimal leaf-to-stem ratio, maximizing the yield of dry extract per unit area.
• Adaptability: The variety shows high responsiveness to agricultural practices, allowing for intensive production methods compared to the unpredictability of wild harvesting.

The patent, held by E. V. Dumacheva, verifies the legitimacy of the breeding achievement and ensures line purity during reproduction. Utilizing 'Avicenna' at an industrial scale enables agricultural enterprises to transition from foraging to planned cultivation, providing pharmaceutical companies with a consistent input material that meets rigorous quality standards. This solution effectively eliminates the variability inherent in spontaneous harvesting.